Question

In: Accounting

LIVERS INC. Statement of Cash Flows For the Year Ended December 31, 20Y3 Cash flows from...

LIVERS INC.
Statement of Cash Flows
For the Year Ended December 31, 20Y3
Cash flows from operating activities:
Net income   
Adjustments to reconcile net income to net cash
flow from operating activities:
Depreciation   
Loss on inventory write down and fixed assets Gain on sale of investments   
Changes in current operating assets and liabilities:
Increase in accounts receivable   
Increase in inventories   
Increase in accounts payable   
Decrease in accrued expenses payable   
Net cash flow from operating activities   
Cash flows from investing activities:
Cash received from sale of investments   
Cash paid for purchase of land   
Cash paid for purchase of equipment   
Net cash flow used for investing activities   
Cash flows from financing activities:
Cash received from sale of common stock   
Cash paid for dividends   
Net cash flow from financing activities   
Change in cash   
Cash at the beginning of the year   
Cash at the end of the year   
Optional:
LIVERS INC.
Spreadsheet (Work Sheet) for Statement of Cash Flows
For the Year Ended December 31, 20Y3
Balance, Transactions Balance,
Dec. 31, 20Y2 Debit Credit Dec. 31, 20Y3
Cash 150,000 155,000
Accounts receivable (net) 400,000 450,000
Inventories 750,000 770,000
Investments 100,000 -
Land - - 500,000
Equipment 1,200,000 1,400,000
Accum. depr. - equipment (500,000) (600,000)
Accounts payable (300,000) (340,000)
Accrued expenses payable (50,000) (45,000)
Dividends payable (25,000) (30,000)
Common stock, $4 par (600,000) (700,000)
Paid-in capital in excess of par (175,000) (200,000)
Retained earnings (950,000) (1,360,000)
Totals - -
Operating activities:
Net income
Depreciation
Gain on sale of investments
Increase in accounts receivable
Increase in inventories
Increase in accounts payable
Decrease in accrued expenses payable
Investing activities:
Purchase of equipment
Purchase of land
Sale of investments
Financing activities:
Declaration of cash dividends
Sale of common stock
Increase in dividends payable
Net change in cash
Totals

Solutions

Expert Solution

Statement of Cash Flow
Particulars Amount Total Amount
Income = 410000+30000             440,000.00
Depreciation             100,000.00
Increase in AR             (50,000.00)
Increase in inventory             (20,000.00)
Increase in AP                40,000.00
Decrease in accrued expenses payable                (5,000.00)
Cash flow from operating activities           505,000.00
Cash flow from Investing activities
Sale of invt             100,000.00
Purchase of Land           (500,000.00)
Sale of PPE           (200,000.00)
Cash flow from Investing activities         (600,000.00)
Cash flow from Financing activities
Issue of Stock             100,000.00
Issue of additional Paid in capital                25,000.00
Dividends Paid             (25,000.00)
Cash flow from Financing activities           100,000.00
net change in cash and cash equivalents                5,000.00
Opening cash and cash equivalents           150,000.00
Closing cash and cash equivalents           155,000.00

ekkarill92 answered 1 year ago
Next > < Previous

Related Solutions

LIVERS INC. Statement of Cash Flows For the Year Ended December 31, 20Y3 Cash flows from...
LIVERS INC. Statement of Cash Flows For the Year Ended December 31, 20Y3 Cash flows from operating activities: Net income    Adjustments to reconcile net income to net cash flow from operating activities: Depreciation 100,000 Loss on inventory write down and fixed assets Gain on sale of investments    Changes in current operating assets and liabilities: Increase in accounts receivable (50,000) Increase in inventories (20,000) Increase in accounts payable 40,000 Decrease in accrued expenses payable (5,000) Net cash flow from...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $300,080 $277,530 Accounts receivable (net) 108,710 99,680 Inventories 306,860 295,120 Investments 0 114,340 Land 157,400 0 Equipment 338,580 260,920 Accumulated depreciation—equipment (79,270) (70,360) Total assets $1,132,360 $977,230 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $204,960 $192,510 Accrued expenses payable (operating expenses) 20,380 25,410 Dividends payable 11,320 8,800 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $222,990 $209,100 Accounts receivable (net) 80,780 75,100 Inventories 228,030 222,360 Investments 0 86,140 Land 116,960 0 Equipment 251,600 196,590 Accumulated depreciation—equipment (58,900) (53,010) Total assets $841,460 $736,280 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $152,300 $145,050 Accrued expenses payable (operating expenses) 15,150 19,140 Dividends payable 8,410 6,630 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $256,050 $240,660 Accounts receivable (net) 92,760 86,430 Inventories 261,850 255,910 Investments 0 99,140 Land 134,310 0 Equipment 288,900 226,250 Accumulated depreciation—equipment (67,640) (61,010) Total assets $966,230 $847,380 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $174,890 $166,930 Accrued expenses payable (operating expenses) 17,390 22,030 Dividends payable 9,660 7,630 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $292,970 $275,040 Accounts receivable (net) 106,130 98,780 Inventories 299,610 292,480 Investments 0 113,310 Land 153,670 0 Equipment 330,560 258,580 Accumulated depreciation—equipment (77,390) (69,730) Total assets $1,105,550 $968,460 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $200,100 $190,790 Accrued expenses payable (operating expenses) 19,900 25,180 Dividends payable 11,060 8,720 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $313,010 $292,180 Accounts receivable (net) 113,390 104,940 Inventories 320,110 310,700 Investments 0 120,370 Land 164,180 0 Equipment 353,170 274,690 Accumulated depreciation—equipment (82,680) (74,070) Total assets $1,181,180 $1,028,810 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $213,790 $202,680 Accrued expenses payable (operating expenses) 21,260 26,750 Dividends payable 11,810 9,260 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $241,460 $226,680 Accounts receivable (net) 87,470 81,410 Inventories 246,920 241,060 Investments 0 93,390 Land 126,650 0 Equipment 272,440 213,110 Accumulated depreciation—equipment (63,780) (57,470) Total assets $911,160 $798,180 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $164,920 $157,240 Accrued expenses payable (operating expenses) 16,400 20,750 Dividends payable 9,110 7,180 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $291,640 $273,170 Accounts receivable (net) 105,650 98,110 Inventories 298,250 290,480 Investments 0 112,540 Land 152,980 0 Equipment 329,060 256,820 Accumulated depreciation—equipment (77,040) (69,250) Total assets $1,100,540 $961,870 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $199,200 $189,490 Accrued expenses payable (operating expenses) 19,810 25,010 Dividends payable 11,010 8,660 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $301,740 $281,660 Accounts receivable (net) 109,310 101,160 Inventories 308,580 299,510 Investments 0 116,040 Land 158,270 0 Equipment 340,460 264,800 Accumulated depreciation—equipment (79,710) (71,410) Total assets $1,138,650 $991,760 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $206,100 $195,380 Accrued expenses payable (operating expenses) 20,500 25,790 Dividends payable 11,390 8,930 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $256,770 $237,750 Accounts receivable (net) 93,020 85,390 Inventories 262,580 252,830 Investments 0 97,950 Land 134,680 0 Equipment 289,710 223,520 Accumulated depreciation—equipment (67,830) (60,280) Total assets $968,930 $837,160 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $175,380 $164,920 Accrued expenses payable (operating expenses) 17,440 21,770 Dividends payable 9,690 7,530 Common stock,...
ADVERTISEMENT
Subjects
ADVERTISEMENT
Latest Questions
ADVERTISEMENT